Developing new treatments for anxiety using sterol carrier protein inhibitors
Development of sterol carrier protein 2 inhibitors as anxiolytics
This study is exploring a new way to help people with anxiety by blocking a specific protein in the body, which could lead to treatments that work better and have fewer side effects than regular anxiety medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project ID | NIH-11126763 on NIH RePORTER |
What this research studies
This research focuses on finding new ways to treat anxiety disorders by targeting a specific protein called sterol carrier protein-2 (SCP-2). The approach involves inhibiting SCP-2 to enhance the signaling of natural compounds in the body that can help reduce anxiety. By doing so, the researchers aim to create a treatment that has fewer side effects compared to traditional anxiety medications. The study will involve both laboratory experiments and potential clinical trials to evaluate the effectiveness of these new inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are experiencing anxiety disorders.
Not a fit: Patients who do not have anxiety disorders or those who are currently receiving effective treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for individuals suffering from anxiety disorders.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance cannabinoid receptor signaling for anxiety treatment, indicating potential for success in this novel approach.
Where this research is happening
Milwaukee, United States
- Medical College of Wisconsin — Milwaukee, United States (Active)
Researchers
- Principal investigator: Hillard, Cecilia J — Medical College of Wisconsin
- Study coordinator: Hillard, Cecilia J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.